France halts Moderna vaccine for under-30s after jab linked with heart problems

Moderna: Teenage vaccine trials 'successful' says Dr Hilary

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

It came after a nationwide study reportedly confirmed a slight risk of cardiac inflammation associated with mRNA vaccines.

Now French health authorities are advising against the use of the Modern jab.

The study was carried out by the independent medicines safety research group Epi-Phare.

They work closely with the French government.

They have confirmed previous suspicions but noted that cases are rare and do not cast doubt on the effectiveness of the shots.

It looked at all people in France aged 12 to 50 who were hospitalised for myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the tissue surrounding the heart) between May 15 and August 31 of this year.

Results reportedly showed that vaccines from both Pfizer and Moderna increase the risk of these illnesses within seven days of vaccination.

The risk, while low, is higher in men under 30 years old and particularly after a second dose of the Moderna vaccine.

The study reports it was linked to some 132 cases of myocarditis per million doses given.

For Pfizer, the result was nearly 80 percent lower, with the number of cases per million doses estimated at 27.

No deaths have been recorded in patients recording the issues after use.

The US has also delayed approval of the Moderna jab for young people, though last week they recommended use of the Pfizer vaccine for children ages five to 11 after reviewing the risks of myocarditis.

Paediatric cardiologist Matthew Oster said he was “much more worried” about the risks of COVID to young people than the risks posed by the vaccine.

Mahmoud Zureik, who heads up Epi-Phare, added: “When you measure the effectiveness of vaccines against severe cases of COVID-19 against the risks that exist but are rare.

“The value of vaccines is not in doubt.”

The American biotech product was suspended on October 15 in France for booster injections, following the alert issued by several Scandinavian countries concerning a possible increased risk of myocarditis and pericarditis.

The High Authority for Health (HAS) is now “completely advising against Moderna for those under 30”.

The French agency has now recommended the resumption of booster injections with Moderna in the over 30s.

It came after recommendations from the European Medicines Agency (EMA).

They said: “A third dose administered six to eight months after the second dose resulted in an increase in antibody levels in adults whose antibody levels decreased.

“The risk of inflammatory heart disease or other very rare side effects after a booster is carefully monitored.”

Source: Read Full Article